Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) unit Guangdong Hengrui Medicine obtained China's regulatory acceptance for the marketing authorization application of SHR-1819 injection.
The drug is indicated for moderate-to-severe atopic dermatitis in adults, according to a Friday filing with the Shanghai bourse.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.